Results from Phase II vaccine trial announced

The biopharmaceutical company, SELLAS Life Sciences, has presented results from its Phase II galinpepimut-S trial at the 44th Annual European Society for Blood and Marrow Transplantation (EBMT) meeting. Galinpepimut-S is a peptide vaccine that targets WT1, a protein expressed on the surface of myeloma cells, and stimulates a CD4+ and CD8+ immune response. The trial…

Details